Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gantenerumab - Roche

Drug Profile

Gantenerumab - Roche

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 23 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche; Washington University School of Medicine
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 19 Oct 2020 Roche initiates a phase II trial for Alzheimer's disease (Early-stage disease) in USA (SC) (NCT04592341)
  • 10 Sep 2020 Roche completes the phase III SCarlet RoAD trial in Alzheimer's disease in USA, Canada, Argentina, Australia, Belgium, Chile, Brazil, the Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Mexico, the Netherlands, Poland, Portugal, Russia, South Korea, Spain, Sweden, Switzerland, Turkey and United Kingdom (SC) (NCT01224106)
  • 27 Jul 2020 Efficacy data from a phase III trial in Alzheimer's disease (Early-stage disease) presented at the Alzheimer's Association International Conference 2020 (AAIC-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top